According to a new market research study of “Asia Pacific Cell Line Development Serum Market Forecast to 2027 - COVID-19 Impact and Analysis by Type and Application.”The Asia Pacific cell line development serum market is expected to reach US$ 362.87 Mn in 2027 from US$ 215.68 Mn in 2019. The market is estimated to grow with a CAGR of 6.7% from 2020 to 2027. The report highlights trends prevailing in the Asia Pacific cell line development serum market and the factors driving market along with those that act as hindrances.
The Asia Pacific cell line development serum market, based on type, has been segmented into fetal bovine serum, adult bovine serum, porcine serum, horse serum, other animal serum. Fetal bovine serum segment held the largest share and is expected to register the highest CAGR in the market during the forecast period.
The cell line can be defined as cell culture, selected for uniformity from a cell population derived from a usually homogeneous tissue source in a growing medium under controlled conditions. The serum serves as a carrier for enzymes, micronutrients, lipids, and trace elements into the cell and regulates cell membrane permeability. Tissue Engineering has now evolved into the broader area of regenerative medicine, which focuses on developing clinical therapies for the maintenance, repair, replacement, and enhancement of biological function, using cell engineering. Regenerative therapies using cell lines and culture can help the researchers in early-intervention treatment for degenerative diseases and traumatic injuries. Thus, a surge in the use of regenerative medicines propels the cell line development serum market.
Key factors that are driving growth of the Asia Pacific cell line development serum market are increasing adoption of regenerative medicines, rising prevalence of cancer across the globe and increasing investments in R&D by pharmaceutical and biotechnology companies. However, risks associated with cell line contamination is expected to hamper the market during the forecast period.
Lonza, Thermo Fisher Scientific Inc. and Sigma-Aldrich Corporation (Merck KGaA) are among the leading companies operating in the Asia Pacific cell line development serum market.
The report segments in Asia Pacific Cell Line Development Serum Market as follows:
By Type
By Application
By Country
Reasons to Buy
The Asia Pacific cell line development serum market, based on type, has been segmented into fetal bovine serum, adult bovine serum, porcine serum, horse serum, other animal serum. Fetal bovine serum segment held the largest share and is expected to register the highest CAGR in the market during the forecast period.
The cell line can be defined as cell culture, selected for uniformity from a cell population derived from a usually homogeneous tissue source in a growing medium under controlled conditions. The serum serves as a carrier for enzymes, micronutrients, lipids, and trace elements into the cell and regulates cell membrane permeability. Tissue Engineering has now evolved into the broader area of regenerative medicine, which focuses on developing clinical therapies for the maintenance, repair, replacement, and enhancement of biological function, using cell engineering. Regenerative therapies using cell lines and culture can help the researchers in early-intervention treatment for degenerative diseases and traumatic injuries. Thus, a surge in the use of regenerative medicines propels the cell line development serum market.
Key factors that are driving growth of the Asia Pacific cell line development serum market are increasing adoption of regenerative medicines, rising prevalence of cancer across the globe and increasing investments in R&D by pharmaceutical and biotechnology companies. However, risks associated with cell line contamination is expected to hamper the market during the forecast period.
Lonza, Thermo Fisher Scientific Inc. and Sigma-Aldrich Corporation (Merck KGaA) are among the leading companies operating in the Asia Pacific cell line development serum market.
The report segments in Asia Pacific Cell Line Development Serum Market as follows:
By Type
- Fetal Bovine Serum
- Adult Bovine Serum
- Porcine Serum
- Horse Serum
- Other Animal Serum
By Application
- Bioproduction
- Drug Discovery
- Tissue Engineering and Regenerative Medicines
- Toxicity Testing
- Academic Research
By Country
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific cell line development serum market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cell line development serum market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. Cell Line Development Serum - Market Landscape
5. Cell Line Development Serum Market - Key Market Dynamics
6. Cell Line Development Serum Market - Asia Pacific Analysis
7. Cell Line Development Serum Market - Revenue and Forecasts to 2027 - Type
8. Cell Line Development Serum Market Analysis and Forecasts to 2027 - Application
9. Cell Line Development Serum Market Revenue and Forecast to 2027 - Asia Pacific Analysis
10. Impact Of COVID-19 Pandemic on Asia Pacific Cell Line Development Serum Market
11. Company Profiles
12. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Lonza
- Thermo Fisher Scientific Inc.
- Sigma-Aldrich Corporation (Merck KGaA)
- Cytiva (Danaher)
- Bovogen Biologicals Pty Ltd
- Corning Incorporated
- WuXi AppTec
- American Type Culture Collection (ATCC)
